ClinicalTrials.gg
Not yet recruitingNCT07938866Updated Nov 16, 2026

Genomic Predictors of Response to CAR-T and BiTE Therapies in B-cell Non-Hodgkin Lymphomas

An observational study in Non-Hodgkin Lymphoma Refractory/ Relapsed, sponsored by Duke University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Duke University · Observational

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
240
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this prospective, non-therapeutic study is to evaluate molecular and clinical factors associated with clinical outcomes following CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy and bispecific T-cell engager (BiTE) therapies in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R NHL).

Read the detailed description

This work builds on prior research from co-investigator Dr Sandeep Dave, in the Departments of Medicine and Engineering. The Dave lab has previously developed a clinically validated genetic assay for paired DNA and RNA sequencing (DuoSeq). More recently, the Dave lab utilized DuoSeq in a cohort of R/R NHL to identify and retrospectively validate a genomic signature associated with outcomes following CAR-T therapy. The primary goal of the proposed study is to prospectively validate this previously developed molecular signature in patients receiving CAR-T therapy. In addition, the proposed study aims to develop a complementary prognostic model for patients receiving BiTE therapy.

02

Conditions studied

  • Non-Hodgkin Lymphoma Refractory/ Relapsed

Keywords

  • CAR-T therapy
  • BiTE therapy
03

In context

Lead sponsor

Duke University is the lead sponsor of 2,064 studies on the registry; 273 are open to participants now.

Of its 204 completed or terminated interventional studies of FDA-regulated products, 167 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Duke inpatients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R NHL)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged ≥18 years
  • Have non-Hodgkin lymphoma (R/R NHL)
  • Are being considered for currently FDA approved CAR-T therapy (Axicabtagene ciloleucel, Tisagenlecleucel, Lisocabtagene maraleucel, or Brexucabtagene autoleucel) or BiTE therapy (Epcoritamab-bysp, Glofitamab-gxbm, or Mosunetuzumab-axgb) at the discretion of their treating oncologist

Exclusion criteria

Exclusion:

  • Are being considered for experimental CAR-T or BiTE therapy at the discretion of their treating oncologist
  • Pre-treatment tissue not available for paired NGS
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
240 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Registry Patients

    Patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R NHL)

06

What researchers measure

Primary outcomes

  1. Number of participants who achieve complete remission (CR) following CAR-T therapy

    Time frame: From enrollment to 360 days after CAR-T/BiTE therapy

Secondary outcomes

  1. Number of participants with progression-free survival (PFS) at 1 year

    Time frame: From CAR-T treatment to documented disease progression or death from any cause, whichever occurs first (up to 1 year)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Nov 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartEst.
Nov 15, 2026
Primary completionEst.
Nov 15, 2028
CompletionEst.
May 15, 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938866
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Nov 15, 2026 (estimated)
Primary completion
Nov 15, 2028 (estimated)
Completion
May 15, 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Shambhavi Singh, M.D., Ph.D.
Contact
ss1691@duke.edu
+1 919 684 6199

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion